Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDANASDAQ:BLRXNASDAQ:PTPINASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.02-2.9%$2.25$1.63▼$4.66$10.77M0.83261,658 shs30,824 shsBLRXBioLineRx$4.00-5.7%$3.82$2.30▼$35.60$18.07M1.29232,693 shs148,093 shsPTPIPetros Pharmaceuticals$0.03+6.4%$0.31$0.02▼$16.25$938K1.573.14 million shs997,598 shsSNSESensei Biotherapeutics$8.06+5.2%$7.15$5.00▼$17.40$9.65M0.145,238 shs17,736 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia0.00%-4.59%+5.58%-20.00%-30.67%BLRXBioLineRx0.00%-9.59%+15.85%+23.98%-82.03%PTPIPetros Pharmaceuticals0.00%-8.39%-27.18%-98.40%-99.72%SNSESensei Biotherapeutics0.00%+27.67%+29.61%-17.56%-41.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia3.5358 of 5 stars3.85.00.00.00.02.50.6BLRXBioLineRx2.9753 of 5 stars3.85.00.00.01.10.01.3PTPIPetros Pharmaceuticals0.2385 of 5 stars0.03.00.00.00.00.80.6SNSESensei Biotherapeutics4.4564 of 5 stars3.75.00.04.80.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,137.62% UpsideBLRXBioLineRx 3.50Strong Buy$26.00550.00% UpsidePTPIPetros Pharmaceuticals 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.33Buy$90.001,016.63% UpsideCurrent Analyst Ratings BreakdownLatest PTPI, SNSE, BLRX, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/2/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$100.005/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/1/2025SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/2/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/31/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $26.003/28/2025SNSESensei BiotherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $80.003/28/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K174.39N/AN/A$0.18 per share11.22BLRXBioLineRx$28.94M0.59N/AN/A$4.04 per share0.99PTPIPetros Pharmaceuticals$5.11M0.18N/AN/A$4.04 per share0.01SNSESensei BiotherapeuticsN/AN/AN/AN/A$30.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)BLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/21/2025 (Estimated)PTPIPetros Pharmaceuticals-$8.16M-$119.00N/A∞N/AN/A-78.22%-23.50%N/ASNSESensei Biotherapeutics-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)Latest PTPI, SNSE, BLRX, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/6/2025Q1 2025SNSESensei Biotherapeutics-$4.20-$5.40-$1.20-$0.27N/AN/A3/28/2025Q4 2024SNSESensei Biotherapeutics-$5.40-$5.40N/A-$0.31N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.360.36BLRXBioLineRx0.372.272.04PTPIPetros Pharmaceuticals1.580.850.74SNSESensei BiotherapeuticsN/A6.826.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%BLRXBioLineRx1.56%PTPIPetros Pharmaceuticals12.34%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%BLRXBioLineRx1.10%PTPIPetros Pharmaceuticals12.25%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.18 million4.14 millionOptionableBLRXBioLineRx404.26 million4.22 millionOptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableSNSESensei Biotherapeutics401.26 million968,000Not OptionablePTPI, SNSE, BLRX, and BCDA HeadlinesRecent News About These CompaniesSensei Biotherapeutics to execute 1-for-20 reverse stock splitJune 13, 2025 | kalkinemedia.comSensei Biotherapeutics Announces 1-for-20 Reverse Stock SplitJune 13, 2025 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressMay 6, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 2, 2025 | globenewswire.comSensei Biotherapeutics announces initial results from solnerstotug trial portionMarch 29, 2025 | markets.businessinsider.comSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical ProgressMarch 28, 2025 | globenewswire.comSensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant TumorsMarch 27, 2025 | globenewswire.comWhat Makes Sensei Biotherapeutics (SNSE) a New Buy StockFebruary 6, 2025 | zacks.comSensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | markets.businessinsider.comSensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comSensei Biotherapeutics Inc (SNSE) Stock: Unveiling Its Hidden StrengthsJanuary 18, 2025 | bovnews.comSensei Biotherapeutics provides update, highlights key upcoming milestonesJanuary 9, 2025 | markets.businessinsider.comPromising Outlook for Sensei Biotherapeutics: Buy Rating Backed by SNS-101 Development and Financial ProjectionsJanuary 9, 2025 | markets.businessinsider.comSensei Biotherapeutics Inc (SNSE) Stock Trading RecapJanuary 9, 2025 | bovnews.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesJanuary 8, 2025 | globenewswire.comSensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare ConferenceNovember 28, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsPTPI, SNSE, BLRX, and BCDA Company DescriptionsBioCardia NASDAQ:BCDA$2.02 -0.06 (-2.88%) Closing price 04:00 PM EasternExtended Trading$2.06 +0.04 (+1.73%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.BioLineRx NASDAQ:BLRX$4.00 -0.24 (-5.66%) Closing price 04:00 PM EasternExtended Trading$4.02 +0.02 (+0.50%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Petros Pharmaceuticals NASDAQ:PTPI$0.03 +0.00 (+6.36%) As of 03:48 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Sensei Biotherapeutics NASDAQ:SNSE$8.06 +0.40 (+5.22%) Closing price 04:00 PM EasternExtended Trading$8.04 -0.03 (-0.31%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
